Jazz Pharmaceuticals JAZZ Licensing Arrangements
Licensing Arrangements at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's licensing arrangements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Jazz Pharmaceuticals's licensing arrangements?
- Jazz Pharmaceuticals (JAZZ) reported licensing arrangements of $47.6M in Q1 2026.
- How has Jazz Pharmaceuticals's licensing arrangements changed year-over-year?
- Jazz Pharmaceuticals's licensing arrangements increased by 62.6% year-over-year, from $29.27M to $47.6M.
- What is the long-term trend for Jazz Pharmaceuticals's licensing arrangements?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's licensing arrangements has grown at a 25.3% compound annual growth rate (CAGR), from $15.23M to $47.1M.